Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder

被引:45
作者
Gee, JR
Montoya, RG
Khaled, HM
Sabichi, AL
Grossman, HB
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
[2] NCI, Dept Med Oncol, Cairo, Egypt
[3] Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA
关键词
bladder cancer; cytokeratin; 20; cyclooxygenase-2; prostaglandin dehydrogenase; bilharziasis;
D O I
10.1016/S1078-1439(02)00271-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bladder tumors from Egyptian patients with a high prevalence of bilharziasis were immunohistochemically analyzed for the expression of cytokeratin 20 (CK20), AN43, prostaglandin dehydrogenase (PGDH), and cyclooxygenase-2 (COX-2). The tumors included 26 transitional cell carcinomas (TCC), 10 squamous cell carcinomas (SCC) and 2 tumors of mixed TCC/SCC histology. Of the 28 TCC tumors, 21 (75%) expressed CK20 and 25 (89%) expressed AN43. CK20 was not expressed in any of the 10 SCC tumors and AN43 was expressed in 2 of them. PGDH was expressed in 18 (64%) of the 28 tumors with TCC histology and 1 of the 10 SCC. A subset of 21 tumors (16 TCC and 5 SCC) was tested for COX-2 expression. COX-2 was detected in 69% of the 16 TCC tumors examined but was not seen in the SCC tumors. As tumors increased in stage, the expression of these proteins changed. CK20, AN43 and PGDH decreased but COX-2 expression increased in higher stage tumors. The histologic phenotype of these cancers is reflected in their expression of these proteins and is modified further as tumors progress in stage. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:266 / 270
页数:5
相关论文
共 15 条
[1]  
Celis JE, 2000, ELECTROPHORESIS, V21, P2115
[2]   Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases [J].
Chu, PG ;
Wu, E ;
Weiss, LM .
MODERN PATHOLOGY, 2000, 13 (09) :962-972
[3]   Bladder cancer in Africa: Update [J].
El Mawla, NG ;
El Bolkainy, MN ;
Khaled, HM .
SEMINARS IN ONCOLOGY, 2001, 28 (02) :174-178
[4]  
Gee Jason Robert, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P264
[5]   Cytokeratin 20 as an objective marker of urothelial dysplasia [J].
Harnden, P ;
Eardley, I ;
Joyce, AD ;
Southgate, J .
BRITISH JOURNAL OF UROLOGY, 1996, 78 (06) :870-875
[6]   Expression of cytokeratin 20 redefines urothelial papillomas of the bladder [J].
Harnden, P ;
Mahmood, N ;
Southgate, J .
LANCET, 1999, 353 (9157) :974-977
[7]   Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas [J].
Kömhoff, M ;
Guan, YF ;
Shappell, HW ;
Davis, L ;
Jack, G ;
Shyr, Y ;
Koch, MO ;
Shappell, SB ;
Breyer, MD .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (01) :29-35
[8]  
Liebert M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P118
[9]  
LIEBERT M, 1989, CANCER RES, V49, P6720
[10]   Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium - An analysis of cytokeratin 20, p53, and CD44 antigens [J].
McKenney, JK ;
Desai, S ;
Cohen, C ;
Amin, MB .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (08) :1074-1078